CTLA4 and neoplasm: With the aim to investigate whether multiparametric CEST-MRI is able to assess early response to immune checkpoint blockade by detecting therapy-induced metabolic changes within the TME, 4T1 or 67NR tumor-bearing mice were treated with a combination therapy of anti-PD1 and anti-CTLA4.